ARQT Share Price Performance
US$0
-15.65 (-100.00%)
Price US$0
Fair ValueUS$39.99
Share Pricen/a
Narrative Update • Aug 08
Arcutis Biotherapeutics, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 64 Fair Values set on narratives written by author
ARQT Community Narratives
CO
Fair Value
·Fair Value US$39.99 37.8% undervalued intrinsic discount
Very Bullish
5users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
Fair Value
·Fair Value US$36.88 32.6% undervalued intrinsic discount
Analysts Cite Strong Sales and Pipeline as Arcutis Biotherapeutics Price Target Rises
0users have liked this narrative
0users have commented on this narrative
34users have followed this narrative
Very Bullish
It is almost impossible to obtain a drug label from the FDA for pediatric use - this topical non-steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.Read more
CO
US$39.99
37.8% undervalued intrinsic discount
Fair Value
Profit Margin
21.21%
Future PE
29.38x
Price in 2030
US$55.82
Analysts Cite Strong Sales and Pipeline as Arcutis Biotherapeutics Price Target Rises
Arcutis bets big on ZORYVE, as wider use in more skin conditions and better insurance access could help it grow beyond its current niche. The flip side is that so much rides on one medicine—if coverage, competition, or spending goes the wrong way, the story can change quickly.Read more
AN
US$36.88
32.6% undervalued intrinsic discount
Fair Value
Revenue
24.24% p.a.
Profit Margin
38.48%
Future PE
19.24x
Price in 2029
US$45.49
Trending Discussion
No trending discussion available.
Recently Updated Narratives
CO
Very Bullish
Fair Value: US$39.99 37.8% undervalued intrinsic discount
12 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
1 likeusers have liked this narrative
AN
ARQT: Expanded Pediatric Dermatology Indications Will Drive Future Upside Potential
Fair Value: US$36.88 32.6% undervalued intrinsic discount
34 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Arcutis Biotherapeutics, Inc. Key Details
About ARQT
- Founded
- 2016
- Employees
- 354
- CEO
- WebsiteView website
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
